期刊
JOURNAL OF CLINICAL PATHOLOGY
卷 65, 期 11, 页码 1019-1023出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jclinpath-2012-200826
关键词
-
类别
资金
- New Energy and Industrial Technology Development Organization, Ministry of Economy, Trade and Industry, Japan
Background and aims Molecular target therapy against L-type amino acid transporter 1 (LAT1) is unique and expected to be developed soon. LAT1 expression was investigated in pancreatic cancer as a prognostic predictor. Methods Surgically resected pancreatic ductal adenocarcinomas (PDAC, n = 66) were investigated using immunohistochemistry. For reference, intraductal papillary mucinous carcinomas (IPMC, including intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia or with an associated invasive carcinoma, n = 13) and adenomas (IPMA, including IPMN with low- and intermediate-grade dysplasia, n = 5) were also examined. Results LAT1 expression scores increased from PDAC to IPMA to IPMC. Kaplan-Meier analysis showed significant differences between LAT1-high and -low scores in PDAC. Even in each Ki-67-labelling index (LI) low and high PDAC group (cut off 40%), high LAT1 expression could also predict poor prognosis. Multivariable analysis showed that LAT1 expression, Ki-67 LI, tumour differentiation and size were individual prognostic factors. Conclusions LAT1 aberrant overexpression in PDAC predicts poor prognosis, independent of Ki-67 LI, and offers a potential target for future anticancer therapy with its inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据